New biomarkers in non-Hodgkin lymphoma and acute leukemias

Rubio-Jurado, Benjamín; Sosa-Quintero, Lluvia Sugey; Carrasco-Martinez, Ivette Lenina; Norato-Delgado, Armando; García-Luna, Eduardo; Guzmán-Silahua, Sandra; Riebeling-Navarro, Carlos; Nava-Zavala, Arnulfo Hernán

doi:10.1016/bs.acc.2019.11.002

Cited by 6 publications

(7 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Expresión de genes: para su evaluación se requieren técnicas para inmovilizar varias secuencias de cDNA; con nuevas tecnologías se puede medir la expresión de múltiples genes de manera simultánea. 45…”

Section: Biomarcadores Pronósticos En Linfoma No Hodgkinunclassified

See 1 more Smart Citation

Biomarcadores serológicos de riesgo en linfoma no Hodgkin

Sosa-Quintero,

Barreno-Rocha,

Guzmán-Silahua

et al. 2023

Salud Jalisco

Self Cite

View full text Add to dashboard Cite

Los linfomas pertenecen a un grupo de neoplasias que se originan de la proliferación maligna de los linfocitos. Globocan reporta que, en México, el linfoma no Hodgkin (LNH) ocupa el undécimo lugar en nuevos casos con 5,174 al año, así como el undécimo lugar en fallecimientos con 2,741 al año, con una prevalencia a los cinco años de 14,189 casos. A través del tiempo, varios índices pronósticos fundamentados en las características clínicas del paciente han permitido establecer el perfil pronostico basado en factores identificados, que posibilitan implementar estrategias de tratamiento. Los estudios moleculares permiten identificar nuevos biomarcadores relacionados con los linfomas a nivel genético, epigénetico y proteómico, así como en el microambiente tumoral. La aplicación de tecnologías de secuenciación de nueva generación ofrece la oportunidad para la detección de nuevos biomarcadores moleculares implicados en los mecanismos fisiopatológicos de la linfomagénesis, que permiten mejorar la clasificación, el diagnóstico y el pronóstico. Ante la emergencia de numerosos biomarcadores existe el reto de seleccionar aquellos que pueden ser aplicables y reproducibles en la práctica clínica para validarlos e identificar su costo-efectividad. La interacción dinámica de los diferentes factores involucrados en el desarrollo, evolución y pronóstico de los linfomas, además de la aplicación adecuada de biomarcadores, facilitará la transición a una medicina personalizada en pacientes con linfoma.

show abstract

Section: Biomarcadores Pronósticos En Linfoma No Hodgkinunclassified

“…La conducción de un nuevo modelo de riesgo debe de utilizar características moleculares. 45 En tiempos recientes se incluyen como determinantes de riesgo la presencia o ausencia de marcadores celulares y citogenéticos, alguno de ellos NF-kB, CXCR4, NYC. 45…”

Section: Células Endoteliales Progenitoras (Epc)unclassified

Biomarcadores serológicos de riesgo en linfoma no Hodgkin

Sosa-Quintero,

Barreno-Rocha,

Guzmán-Silahua

et al. 2023

Salud Jalisco

Self Cite

View full text Add to dashboard Cite

show abstract

“…Non-Hodgkin's lymphoma (NHL) is the most common hematologic neoplasia characterized by the abnormal development of lymphocytes, affecting the lymph nodes, spleen, bone marrow, stomach and skin. [9]. In 2020, NHL caused the death of 259,793 individuals worldwide [10].…”

Section: Introductionmentioning

confidence: 99%

In Vivo, In Vitro and In Silico Anticancer Activity of Ilama Leaves: An Edible and Medicinal Plant in Mexico

Ramírez-Santos,

Calzada,

Ordoñez-Razo

et al. 2024

Molecules

View full text Add to dashboard Cite

Ilama leaves are an important source of secondary metabolites with promising anticancer properties. Cancer is a disease that affects a great number of people worldwide. This work aimed to investigate the in vivo, in vitro and in silico anticancer properties of three acyclic terpenoids (geranylgeraniol, phytol and farnesyl acetate) isolated from petroleum ether extract of ilama leaves. Their cytotoxic activity against U-937 cells was assessed using flow cytometry to determine the type of cell death and production of reactive oxygen species (ROS). Also, a morphological analysis of the lymph nodes and a molecular docking study using three proteins related with cancer as targets, namely, Bcl-2, Mcl-1 and VEGFR-2, were performed. The flow cytometry and histomorphological analysis revealed that geranylgeraniol, phytol and farnesyl acetate induced the death of U-937 cells by late apoptosis and necrosis. Geranylgeraniol and phytol induced a significant increase in ROS production. The molecular docking studies showed that geranylgeraniol had more affinity for Bcl-2 and VEGFR-2. In the case of farnesyl acetate, it showed the best affinity for Mcl-1. This study provides information that supports the anticancer potential of geranylgeraniol, phytol and farnesyl acetate as compounds for the treatment of cancer, particularly with the potential to treat non-Hodgkin’s lymphoma.

show abstract

“…Biomarkers can be predictive and helpfully selected for the treatment program when diagnosed with malignant diseases [18].…”

Section: Introductionmentioning

confidence: 99%

“…Biomarkers are useful in confirming malignant or benign diseases with asymptomatic subjects in the early stages of cancer and in patients examined for neoplastic diseases. Biomarkers can be predictive and helpfully selected for the treatment program when diagnosed with malignant diseases [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment

et al. 2022

View full text Add to dashboard Cite

B-cell lymphomas exhibit a vast variety of clinical and histological characteristics that might complicate the diagnosis. Timely diagnosis is crucial, as treatments for aggressive subtypes are considered successful and frequently curative, whereas indolent B-cell lymphomas are incurable and often need several therapies. The purpose of this review is to explore the current advancements achieved in B-cell lymphomas metabolism and how these indicators help to early detect metabolic changes in B-cell lymphomas and the use of predictive biological markers in refractory or relapsed disease. Since the year 1920, the Warburg effect has been known as an integral part of metabolic reprogramming. Compared to normal cells, cancerous cells require more glucose. These cancer cells undergo aerobic glycolysis instead of oxidative phosphorylation to metabolize glucose and form lactate as an end product. With the help of these metabolic alterations, a novel biomass is generated by the formation of various precursors. An aggressive metabolic phenotype is an aerobic glycolysis that has the advantage of producing high-rate ATP and preparing the biomass for the amino acid, as well as fatty acid, synthesis needed for a rapid proliferation of cells, while aerobic glycolysis is commonly thought to be the dominant metabolism in cancer cells. Later on, many metabolic biomarkers, such as increased levels of lactate dehydrogenase (LDH), plasma lactate, and deficiency of thiamine in B-cell lymphoma patients, were discovered. Various kinds of molecules can be used as biomarkers, such as genes, proteins, or hormones, because they all refer to body health. Here, we focus only on significant metabolic biomarkers in B-cell lymphomas. In conclusion, many metabolic biomarkers have been shown to have clinical validity, but many others have not been subjected to extensive testing to demonstrate their clinical usefulness in B-cell lymphoma. Furthermore, they play an essential role in the discovery of new therapeutic targets.

show abstract

New biomarkers in non-Hodgkin lymphoma and acute leukemias

Cited by 6 publications

References 85 publications

Biomarcadores serológicos de riesgo en linfoma no Hodgkin

Biomarcadores serológicos de riesgo en linfoma no Hodgkin

In Vivo, In Vitro and In Silico Anticancer Activity of Ilama Leaves: An Edible and Medicinal Plant in Mexico

Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment

Contact Info

Product

Resources

About